Under construction – not a live service
Sign in
Taking people in SwitzerlandNo phase

Collects samples from people with myeloma and related plasma cell conditions

Collects and stores biological samples from adults with myeloma or related conditions.

Key facts

Who runs it
European Myeloma Network B.V.
Where
Lausanne and Sankt Gallen, SwitzerlandSee the 2 sitesAlso in 9 other countries, 39 sites
Trial code
Registry title
European Myeloma Network (EMN) Sample Project
Status
Recruiting
People taking part
6,000 people, planned
Started
21 Dec 2022
Expected to end
Dec 2037
Type of study
Observational
Treatments tested
  • storage of biological samples
Record updated
3 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with MGUS, smouldering myeloma, multiple myeloma or plasma cell leukemia. It collects and stores blood and other samples for research.

Age
18 years or older
Sex
All sexes can join
Disease stage
MGUS, smouldering multiple myeloma, multiple myeloma, or plasma cell leukemia, with or without extramedullary disease (disease outside the bone marrow)
Earlier treatment
No earlier treatment for myeloma. One course of therapy is allowed if the doctor judged urgent treatment necessary.

Main reasons for not taking part

  • Earlier treatment for myeloma (apart from one urgent course)
  • Serious reactions to giving blood before, such as fainting, angina, severe bruising or allergic reactions
  • Conditions that could make it hard to follow the trial plan and visits
  • Not able to give written consent

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Subjects with MGUS, smouldering Multiple Myeloma (SMM) , MM (Multiple Myeloma) (+/- EMD), plasma cell leukemia (PCL) (+/- EMD)
  • Subjects are ≥ 18 years old
  • Subjects have provided written informed consent in accordance with federal, local, and institutional guidelines prior to initiation of any project-specific activities or procedures; Subjects do not have kind of condition that, in the opinion of the Investigators, may compromise the ability of the subjects to give written informed consent and; subjects are, in the investigator's opinion, willing and able to comply with the protocol requirements

Who cannot take part

  • Previous treatment with anti-myeloma therapy (excluding one course of therapy in patients in which urgent therapy is deemed necessary according to physician's discretion, e.g. myeloma-related complications resistant to supportive care)
  • Subjects have had prior unforeseen (serious) adverse reactions to blood donation including, but not limited to fainting, angina, severe bruising, allergic reactions, or any other adverse events
  • Any psychological, familial, sociological and geographical condition potentially hampering compliance with the protocol and follow-up schedule

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Which of these best describes your myeloma treatment so far?

Where in Switzerland

Also in 9 other countries, 39 sites

  • CHUVLausanne, SwitzerlandContact: Auner (principal investigator)Taking people
  • HOCH Health Ostschweiz - Kantonsspital St. GallenSankt Gallen, SwitzerlandContact: Driessen (principal investigator)Taking people

About the trial

What the trial wants to find out

This is an observational, non-interventional, multicenter study for the prospective collection, storage and analysis of patients' biological samples.

Read full original descriptionShow less

This study establishes a common international infrastructure useful to collect standard clinical variables at baseline and during treatment and to uniformly collect and store biological samples

The group in the trial

  • Subjects with MGUS, SMM, MM, PCL

    Subjects with Monoclonal Gammopathy of Undetermined Significance (MGUS), smouldering Multiple Myeloma (SMM), Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) Timepoints and samples to be collected are the following: * bone marrow aspirate, bone marrow biopsy, EMD biopsy, peripheral blood and serum at baseline; * bone marrow aspirate, bone marrow biopsy, peripheral blood and serum pre-maintenance in TE patients or after 1 year of therapy in Non-Transplant-Eligible (NTE) patients; * bone marrow aspirate, bone marrow biopsy, peripheral blood and serum during maintenance therapy and only if performed as SOC; * bone marrow aspirate, bone marrow biopsy, EMD biopsy peripheral blood and serum at 1st and later PD.

    Treatment: storage of biological samples

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
EMN Prospective Sample Collection Project
Plain-language title
Collects samples from people with myeloma and related plasma cell conditionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06237803, who can take part
Record updated
3 December 2025